Clinical Trials
119 trialsSBRT for Oligo-residual NSCLC After Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
Fudan University
Chemoradiotherapy With or Without Metformin in Locally Advanced Cervical Cancer
Peking Union Medical College Hospital
Nim-PC-28
Peking University Third Hospital
Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide
Instituto do Cancer do Estado de São Paulo
Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)
Henan Cancer Hospital
Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI
Guangzhou University of Traditional Chinese Medicine
Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma
Eye & ENT Hospital of Fudan University
SNMM
Eye & ENT Hospital of Fudan University
LpDessai
Centre Hospitalier Universitaire de Besancon
Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma
Jiangsu Cancer Institute & Hospital
Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
DIPG
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer
Peking Union Medical College Hospital
IMPROVE
Fudan University
PROACH
Ruijin Hospital
DEDALUS
Fondazione IRCCS Policlinico San Matteo di Pavia
Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.
Henan Cancer Hospital
Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC
Zhejiang University
HIST-RIC
Institut Paoli-Calmettes
Induction Chemotherapy Followed by Short Course Radiotherapy in Rectal Cancer
Salah Azaïz Cancer Institute
Efficacy and Safety of Tirelizumab Plus Chemotherapy Versus Chemotherapy Alone in Patients With Lymph Node Positive Gastric Cancer After Surgery
Yixing People's Hospital
Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)
Tianjin Medical University Cancer Institute and Hospital
Clinical Study of Neoadjuvant PD-1 Antibody (Toripalimab) Plus Chemotherapy for Locally Advanced Thymic Epithelial Tumor
Shanghai Pulmonary Hospital, Shanghai, China
MILES-5
National Cancer Institute, Naples
Intraperitoneal Chemotherapy in Gastric Cancer With Peritoneal Carcinomatosis
Instituto do Cancer do Estado de São Paulo
COLT
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma.
Shandong Cancer Hospital and Institute
Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC
Sun Yat-sen University
Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC（NICE-RT）
Shanghai Chest Hospital
A Study to Evaluate Inetetamab + Pyrotinib + Chemotherapy in Previously Untreated HER2-Positive Metastatic Breast Cancer
Fujian Medical University
Zimberelimab Combined With Concurrent Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer
Shanghai Zhongshan Hospital
Neoadjuvant Treatment of Fruquintinib Combined With Concurrent Chemoradiotherapy for LARC
Henan Provincial People's Hospital
Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations
Tianjin Medical University Cancer Institute and Hospital
IMCORT-2
Sichuan Cancer Hospital and Research Institute
Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab in the De Novo Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer
Zhongda Hospital
FOLRT
Campus Bio-Medico University
Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPC
Eye & ENT Hospital of Fudan University
A Clinical Study of Immunotherapy Combined With Chemotherapy and Anti-angiogenic Therapy in Operable NSCLC
Second Xiangya Hospital of Central South University
WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC
Shandong Cancer Hospital and Institute
Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer
Shanghai Zhongshan Hospital
Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer
The Affiliated Hospital of Xuzhou Medical University
Immunopheresis Alone or in Combination With Paclitaxel or Atezolizumab in Non-small Cell Lung Cancer (NSCLC).
Immunicom Inc
Envafolimab Combined With Chemotherapy and Recombinant Human Endostatin in the First-line Treatment of Sq-NSCLC
Qilu Hospital of Shandong University
Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary
Shanghai Changzheng Hospital
A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer
Zhejiang Cancer Hospital
Clinical Study of Camrelizumab Combined With SOX in the Adjuvant Treatment of Advanced Gastric Adenocarcinoma or Gastric Esophageal Junction Adenocarcinoma
The Second Affiliated Hospital of Shandong First Medical University
Effectiveness of Neoadjuvant Chemotherapy Combined With PD-1 Monoclonal Antibody in the Treatment of Operable Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Soochow University
Clinical Study of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Non-small Cell Lung Cancer
The Second Affiliated Hospital of Shandong First Medical University
A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer
The Second Affiliated Hospital of Shandong First Medical University